

AD _____

Award Number: W81XWH-09-1-0364

TITLE: Purinergic Receptors in Quiescence and Localization of Leukemic Stem Cells

PRINCIPAL INVESTIGATOR: Byeong-Chel Lee, Ph.D.

CONTRACTING ORGANIZATION: University of Pittsburgh
Pittsburgh, PA 15213

REPORT DATE: May 2011

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE May 2011		2. REPORT TYPE Annual		3. DATES COVERED 1 May 2010 – 30 April 2011	
4. TITLE AND SUBTITLE Purinergic Receptors in Quiescence and Localization of Leukemic Stem Cells				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-09-1-0364	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Byeong-Chel Lee, Ph.D. E-Mail: leeb4@upmc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pittsburgh Pittsburgh, PA 15213				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT A small subpopulation of drug- and radiation-resistant leukemia is an immediate concern for leukemia patients as this subtype remains the actual cause of morbidity and mortality. Our preliminary results showed that P2Y14 functions in bone marrow to preserve stem progenitor cells from premature senescence/cell death induced by genotoxic stress. As P2Y14 is highly expressed in differentiation resistant leukemia cells, P2Y14 expression in leukemia cells may function in preserving regenerative capacity by constraining cell death/senescence induction. We also found that P2Y14 axis is associated with stem cell mobilization. By providing a mechanistic insight for the roles of P2Y14 in the genotoxic stress-induced injury, directly documenting the effects of P2Y14/UDP-Glc axis on stem cell mobilization, our preliminary results are expected to provide the foundation for an effective treatment to destroy therapy resistant leukemia cells.					
15. SUBJECT TERMS Leukemic stem cell, purinergic receptor, cellular senescenc					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	16	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	2
Body.....	3
Key Research Accomplishments.....	12
Reportable Outcomes.....	12
Conclusion.....	12
References.....	13
Appendices.....	14

Introduction

Although conventional therapy temporarily lessens the burden of the disease, a lingering subpopulation of drug- and radiation-resistant leukemia may regenerate. This small subpopulation of drug- and radiation-resistant leukemia is an immediate concern for leukemia patients as this subtype remains the actual cause of morbidity and mortality.

Nucleotides, once recognized as mere sources of energy, are now recognized as key extracellular messengers that regulate diverse aspects of homeostasis in various physiological and pathophysiological conditions (1). Extracellular nucleotides exert their actions through interaction with their cognate receptors, purinergic receptors. Purinergic receptors are classified into P1 and P2 receptors, based on their ligand binding and function (2). The role of P2 receptors as regulators of hematopoiesis has become more evident in recent years (3-4). A wide variety of P2 receptors are expressed in blood and inflammatory cells, and their physiological significance has been demonstrated (5).

Recent results defined molecular signatures predicting the drug resistance of leukemia cells (6). P2Y₁₄ expression has been shown to be highly upregulated in differentiation-resistant acute myeloid leukemia (AML) cases in 28 freshly isolated AML blast populations, making the P2Y₁₄ gene a prime suspect of incurable leukemia. P2Y₁₄ is also listed as a target gene of the Wnt3A, whose aberrant regulation is closely associated with hematological malignancies and several types of other cancers (7). In this report, when leukemia cells are treated with Wnt3A, P2Y₁₄ was the gene most strongly upregulated. More recently, a comprehensive mutational analysis of human cancer identified P2Y₁₄ as one of the candidate cancer genes that is mutated at a significant frequency in a large fraction of colorectal cancers (8). It is believed that a similar set of genes controls both normal and cancer stem cells. Therefore, if the genes expressed by normal stem cells are found to be mutated or used differently in cancer cells, it is very likely that those genes play a role in the development of cancer stem cells. Taken together, these studies provide strong evidence that P2Y₁₄ is functionally and molecularly linked to drug-resistant leukemia and possibly other types of cancers. Following our preliminary results also lead to the likelihood that P2Y₁₄ is closely associated not only with maintenance of the normal HSC but also with the dysfunction of the LSC.

Therefore, we hypothesized that the P2Y₁₄ receptor is an important local regulatory molecule that leads to leukemic stem cell migration and quiescence and we aim to investigate

whether manipulating P2Y₁₄/UDP-Glc signaling axis can sensitize leukemic stem cells to conventional cancer therapy.

Body

Specific Aim 1: To investigate how P2Y₁₄ signaling axis regulates the quiescence of LSC

In our previous annual report, we demonstrated that the *P2ry14* deficiency confers hypersusceptibility to irradiation (IR) and/or chemotherapy drug, such as 5-fluorouracil (5-FU). Since it is hypothesized that leukemic stem cells arise either from normal stem cells or from progenitor cells, we further investigated the mechanisms by which P2Y₁₄ mediates the resistance to radiation using *P2ry14* knock-out (KO) mouse. We previously showed that P2Y₁₄ KO LSK cells were preferentially decreased upon total body irradiation (TBI) compared to WT counterparts. Preferential diminution of P2Y₁₄ KO LSK cells under radiation stress could be the result of increased susceptibility of P2Y₁₄ KO LSK cells to IR-induced cell death or increased senescence, or both. Radiation induces both apoptotic and non-apoptotic cell death [Zhuang, 2009 #535]. When we analyzed radiation-induced cell death, there was a trend toward increased IR-induced apoptosis (Annexin V⁺) in P2Y₁₄ KO LSK cells (Fig. 1, left panel). Meanwhile, P2Y₁₄ deficient LSK cells exhibited a significantly higher rate of Annexin V⁻, DAPI⁺ cells (P=0.047) (Fig. 1, lower), suggesting that P2Y₁₄ KO HSPCs die through non-apoptotic rather than apoptotic pathways.




Figure 1: Cell death analysis in gated LSK cells: Cell death was measured by quantification of Annexin V and DAPI positive cells within LSK cells after 8 h TBI (6 Gy). The data are representative of two independent experiments each with bone marrow cells pooled from two mice per group (right). NAC (100mg/Kg) was injected subcutaneously 4 h before and 2 h after TBI. Data are expressed as mean \pm s.d. Representative flow cytometric analysis of Annexin-V and DAPI positive LSK cells from irradiated WT and *P2ry14*^{-/-} mice is shown (left). Percentages of gated cell populations are indicated.

Since sublethal radiation has been reported to selectively induce HSC senescence (9), we used this modality to investigate the role of P2Y₁₄ in IR-induced senescence. LSK cells lacking P2Y₁₄ showed a markedly increased level of SA- β -Gal activity ($p=0.003$), indicating that P2Y₁₄ KO HSPCs are more susceptible to IR-induced senescence (Fig. 2) than WT HSPCs.




Figure 2. Mice of the indicated genotypes were exposed to TBI as described. NAC was administered as described in Figure 1. SA- β -gal activity was determined using C₁₂-FDG. Percentage of SA- β -gal positive LSK population (left) is expressed as mean \pm s.d. The data are representative of at least two independent experiments each with BM cells pooled from three mice per group. Representative histograms of SA- β -gal staining in gated LSK cell (right).

The formation of reactive oxygen species (ROS) by radiation is one of the major direct causes for cellular injury. Hematopoietic stem cells (HSCs) are especially sensitive to oxidative stress (10), and elevated level of ROS has been reported to be a major contributing factor toward loss or functional impairment of HSCs in other settings (10-12). Following IR, significantly higher levels of mitochondrial superoxide were detected in KO Hematopoietic stem progenitor cells (HSPCs) both *in vivo* (Fig. 3A) and *in vitro* (Fig. 3B). The increased ROS level is inversely correlated with mitochondrial membrane potential ($\Delta\psi_m$) and mitochondrial dysfunction is closely associated with impaired HSC function (12). As shown in Fig. 3C, the increased ROS level in P2Y₁₄ KO LSK cells coincided with a low mitochondrial membrane potential ($\Delta\psi_m$).




Figure 3. Analysis of cellular/molecular mechanisms underlying the increased susceptibility of *P2Y*₁₄ deficient HSPCs to genotoxic stress

(A-B) MitoSox staining in gated LSK cells: Mitochondrial accumulation of superoxide was measured with MitoSOX™ Red within LSK cells *in vivo* (6 Gy TBI) (A) and *in vitro* (1.6 Gy, *in vitro* IR) (B). NAC was treated as described. Representative histograms of MitoSox staining in gated LSK cell (A, left). The accompanying graphs show percentage of LSK cells positive for MitoSOX fluorescence *in vivo* (A, right) and *in vitro* (B). The data are representative of at least three independent experiments.

(C) JC-1 staining in gated LSK cells: WT and *P2ry14*^{-/-} BM cells were irradiated as described in (B). A decrease in the ratio of red (FL1: 585 nm) to green (FL2: 530 nm) indicates mitochondrial depolarization. The data are representative of at least three independent experiments each with BM cells pooled from at least two mice per group.

To further test whether IR-induced ROS are indeed responsible for the observed preferential reduction of BM cellularity and LSK cells in *P2Y*₁₄ KO mice, WT and KO mice were treated with the ROS scavenger N-acetyl-cysteine (NAC). NAC treatment reduced levels of superoxide in LSK cells (Fig. 3A) and alleviated the IR-induced cell death (Fig. 1) and

senescence (Fig. 2) in P2Y₁₄ deficient LSK cells. This was accompanied with restoration of BM cellularity and LSK cell number (data not shown).

Hyper-radiosensitivity of P2Y₁₄ KO HSCs may relate to their differential DNA repair capacity. Therefore, we assessed levels of γ -H2AX in WT and P2Y₁₄ deficient LSK cells before and after IR. Similar levels of DNA damage (at 30 min post-IR) and repair (at 6h post-IR) were detected in P2Y₁₄ KO HSPCs in comparison to WT counterparts (Fig. 4). This indicates that P2Y₁₄ KO HSPCs respond normally to DNA double-strand breaks (DSB) and repair DNA damage.




Figure 4. Mice (n=2) of the indicated genotypes were exposed to 6Gy of TBI. The levels of H2AX phosphorylation on gated LSK cells were quantified using anti-phospho-histone H2AX (Ser139) antibody. Numbers denote mean fluorescent intensity (MFI).

Taken together, our preliminary results strongly suggest that the presence of P2Y₁₄ in stem/progenitor cells may determine radio and chemo-resistance of cells. Based on these results, we will continue to investigate whether P2Y₁₄ axis is associated with therapy resistant leukemia phenotypes using the chimeric mice that we established in Specific Aim 2.

Specific Aim 2: To investigate functional correlation between P2Y₁₄ signaling and therapy-resistant leukemia

p38 MAPK has been shown to act downstream of ROS and its activation in HSC can lead to a defect in HSCs (10-11). We thus determined whether P2Y₁₄ KO HSPCs display differential activation of p38 MAPK under genotoxic stress. Since ROS generation occurs within seconds of radiation exposure and persists for 2–5 min post-IR {Leach, 2002 #531}, the activation of p38 MAPK was analyzed at an early time point immediately after TBI. Whereas there was no detectable difference in p38 MAPK activity between WT and KO HSPCs under homeostatic conditions, p38MAPK activity was notably higher in P2Y₁₄ deficient LSK and SLAM LSK cells following radiation (6 Gy, TBI) (Fig. 5, left). Of note, p38 MAPK activation was transient as its level returned to near basal control levels about 5h after TBI (data not shown). NAC treatment almost completely abolished the p38 MAPK activation (Fig 5, right panel). Taken together, our data demonstrate that P2Y₁₄ deficiency confers increased susceptibility to genotoxic stress-induced cell death and senescence in HSPC compartments via the excessive activation of p38 MAPK triggered by IR-induced ROS.




Figure 5. WT (red line) and P2ry14^{-/-} (blue line) mice were exposed to TBI (6Gy). Mice were sacrificed immediately after IR and their LSK (upper) and SLAM LSK (lower) cells were analyzed for phosphorylated p38 MAPK by flow cytometry. NAC was treated as described. Note that p38 MAPK activity was completely abrogated upon NAC treatment. The accompanying graphs (right) show the mean fluorescence intensity of p38 MAPK in LSK (upper) and SLAM (lower) LSK cells. Data are represented as absolute numbers of cells \pm s.d. of at least two independent experiments. The graph on the right displays the mean \pm s.d. fluorescence intensity. Mice were analyzed individually (n >4 mice/each genotype).

p38 MAPK and JNK are critical regulators for the cell survival, apoptosis and cell cycle progression and the aberrant activation of these pathways are potential causes of hematologic malignancies. Therefore, we investigated whether P2Y₁₄/UDP-Glc axis can trigger p38 MAPK and/or JNK signaling pathway in leukemia cells as shown in normal HSPCs. KG-1 cells, an immature leukemia cell line, were treated with UDP-Glc. As shown in Fig. 6, UDP-Glc triggered the activation of both p38 MAPK and JNK pathway in KG-1 leukemia cells starting as early as 5 min after UDP-Glc treatment. For JNK proteins, the activation peaked at 30 min post-treatment and decreased thereafter. Interestingly, p38 MAPK activity reached a peak after 5 min and then sustained its activity over prolonged time. We are currently assessing the impact of these pathways on cell death and senescence in leukemia cells.




Figure 6: UDP-Glc triggers the activation of p38 MAPK and JNK in a P2Y₁₄ expressing immature leukemia cells, KG1. Cells were treated with 100μM UDP-Glc and analyzed for the activation of p38 MAPK and JNK at the indicated times.

We proposed to investigate whether P2Y₁₄/UDP-Glc axis is functionally associated with differentiation-resistant leukemia. For this purpose, we have obtained bone marrow samples from 41 unidentified leukemia patients. Among these samples, five human acute leukemia samples (AML) (M0 or M1) were chosen based on FAB classification, cytogenetic abnormalities, CD34 and CD14 expression (Table 1).

Table1: Morphologic, immunologic, and cytogenetic classification of AML samples

Patient	Age	FAB	Cytogenetic abnormalities	Blast	CD34+	CD14+
104	66	M0/M1	Negative PML-RARA (unlike M2)	92%	35%	0%
133	60-64	M0	ETV6 (TEL) rearrangement t(12;22) (Q13;Q11.2) t(6;15), del(17)	63%	N/A	6%
069	30	M0	11q23 t(11;19)(q23;p13.3), +19	87%	0%	0%
084	69	M0	2+, 3-, 5-, -7, +8, -14, -15 etc. Complex karyotypes	30%	63%	N/A
170	60-64	M0/M1	-4, t(7;11) -6, MLL(11q23)x3, MLLx4~6 etc.	90%	92%	15%

Two of five AML samples failed to engraft in NOD-*scid* *IL2R γ ^{null}* mice. Three AML samples showed detectable human leukemia cells 8 weeks post-transplantation (Fig. 7). Currently, approximately 20 NOD-*scid* *IL2R γ ^{null}* mice have been transplanted. To assess whether we indeed transplanted leukemia initiating cells, BM cells from these engrafted recipients were subjected to secondary transplantation.




Figure 7. Bone marrow cells from AML patients (M0 or M1) were transplanted into NOD/LtSz-scid/IL-2Rgamma null mice. Eight to nine weeks after transplantation, peripheral blood cells from recipient mice were incubated with human-specific antibodies directed to human CD45. Numbers in histograms indicate the percentage of human AML-derived cells.

Specific Aim 3: Examine whether the activation of P2Y₁₄/UDP-Glucose signaling axis mobilizes leukemic stem cells from recipient's bone marrow.

As shown in specific aim 2, while we are in the process of establishing mouse xenograft model system in which primary human leukemic stem cells are engrafted into NOD-*scid* *IL2R γ ^{null}* mice, we further examined whether activation of P2Y₁₄/UDP-Glc signaling axis mobilizes normal stem cells from recipient's bone marrow. UDP-Glc is known to be released into the extracellular space under stresses (13). To investigate whether the administration of UDP-Glc may result in HSPC mobilization, we injected UDP-Glc into mice and assessed for its ability to mobilize CFU-Cs and LSKs into the blood circulation. In determining optimal dose, UDP-Glc exerted its maximal mobilizing effects at a dose of 200mg/kg body weight (data not shown). Although i.v. administration was superior to s.c. or i.p. in mobilizing CFCs (data not shown), s.c. injection was chosen for further studies because of its simplicity and to minimize potential side effects of i.v. injection. There was a noticeable increase in CFU-C (Fig. 8a) and circulating LSKs (Fig. 8b) after 6 daily single UDP-Glc injections.




Fig. 8 *P2Y₁₄/UDP-Glc axis and HSPC mobilization.* PB mobilization was performed by injecting C57/BL6 mice (n=5/group) with 200mg/kg of UDP-Glc given at 24 hr interval. Administration of UDP-Glc led to the mobilization of CFU-Cs (a) and LSKs (b). Data are representative of at least 5 independent experiments; (c) Synergistic mobilization of LSKs by the combination of G-CSF (G) and UDP-Glc (U). U+G, UDP-Glc + G-CSF; (d) UDP-Glc mobilized blood cells (CD45.2, U) were mixed at 1:1 ratio with control (CD45.1, PBS injected) cells and transplanted into recipient mice (CD45, 1.2). The percentage of donor contribution was assessed at 1 and 2 months after transplantation; (e) Longitudinal sections of femurs from UDP-Glc treated (UDP-G) and control PBS-injected (CTL) mice were stained with anti-RANKL antibody; (f) LSKs from UDP-Glc treated (black bar) and untreated (gray bar) mice were analyzed for MMP-9 expression by Q-RT-PCR. The expression was normalized to GAPDH. Q-RT-PCR was done at least two times; data from one representative assay are shown.

Importantly, the frequency of LSKs in the blood of mice treated with UDP-Glc was similar to that obtained with G-CSF treatment (Fig. 8c). Furthermore, UDP-Glc acted in synergy with G-CSF to induce LSK mobilization (Fig. 8c). No animals transplanted with control blood cells (PBS injected) survived to lethal irradiation (data not shown). In contrast, UDP-Glc mobilized cells not only displayed the ability to rescue lethally irradiated recipients but also were far superior to control blood cells in a competitive repopulation assay (Fig. 8d). UDP-Glc-induced mobilization was not the strain-specific phenomenon, since similar results were obtained using Balb/c mice (data not shown). To determine whether UDP-Glc triggers HSPC mobilization through P2Y₁₄ receptor, P2Y₁₄ KO mice were treated with UDP-Glc. UDP-Glc treatment did not result in LSK cell mobilization in KO mice (data not shown), suggesting that UDP-Glc mobilizes LSK cells through P2Y₁₄ signaling axis. Because RANKL induces HSPC mobilization (14), we examined whether UDP-Glc modulates RANKL expression. Indeed, UDP-Glc increased expression of RANKL (Fig. 8e). RANKL promotes HSPC mobilization in part via MMP-9 mRNA upregulation (14). WT LSKs, but not KO LSKs, showed increased expression (1.7-2.5 fold) of MMP-9 upon UDP-Glc treatment (Fig. 8f), which is comparable to the fold increase in RANKL treated mice (14).

As normal HSCs and AML initiating cells are known to share many surface molecule and are supposed to use common mechanisms for their mobilization, these results support our hypothesis leukemia stem cells may use P2Y₁₄/UDP-Glc axis for their localization in bone marrow. Using chimeric recipient mice that established in Specific Aim 2, we will continue to investigate the mobilization of leukemia cells.

Key Research Accomplishments

1. *Successfully established xenograft mouse model system.*
2. *Identify potential mechanisms by which P2Y₁₄ signaling axis mediates radiation and chemoreagent resistance.*
3. *Identify potential mechanisms by which P2Y₁₄ signaling mediates HSC and LSC mobilization.*

Reportable Outcomes

Cho JS, Shen H, Hui Y, Cheng T, Lee SB, Lee BC. 2011. Ewing's Sarcoma Gene EWS regulates Hematopoietic Stem Cell Senescence. *Blood*, 117:1156-66.

Conclusion

How leukemia stem cells gained resistance to radiation and chemotherapy is poorly defined, yet critically determines how leukemia cells tolerate conventional leukemia therapy. Our preliminary results showed that P2Y₁₄ functions in bone marrow to preserve stem progenitor cells from premature senescence/cell death induced by genotoxic stress.

As P2Y₁₄ is highly expressed in differentiation resistant leukemia cells, P2Y₁₄ expression in leukemia cells may function in preserving regenerative capacity by constraining cell death/senescence induction. We also found that P2Y₁₄ axis is associated with stem cell mobilization. By providing a mechanistic insight for the roles of P2Y₁₄ in the stress-induced injury, directly documenting the effects of P2Y₁₄/UDP-Glc axis on stem cell mobilization, our preliminary results are expected to provide the foundation for an effective treatment to destroy therapy resistant leukemia cells.

References

1. Volonte, C., S. Amadio, N. D'Ambrosi, M. Colpi, and G. Burnstock. 2006. P2 receptor web: complexity and fine-tuning. *Pharmacol Ther* 112:264-280.
2. White, N., and G. Burnstock. 2006. P2 receptors and cancer. *Trends Pharmacol Sci* 27:211-217.
3. Di Virgilio, F., P. Chiozzi, D. Ferrari, S. Falzoni, J. M. Sanz, A. Morelli, M. Torboli, G. Bolognesi, and O. R. Baricordi. 2001. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. *Blood* 97:587-600.
4. Sak, K., J. M. Boeynaems, and H. Everaus. 2003. Involvement of P2Y receptors in the differentiation of haematopoietic cells. *J Leukoc Biol* 73:442-447.
5. Di Virgilio, F., P. A. Borea, and P. Illes. 2001. P2 receptors meet the immune system. *Trends Pharmacol Sci* 22:5-7.
6. Tagliafico, E., E. Tenedini, R. Manfredini, A. Grande, F. Ferrari, E. Roncaglia, S. Biciato, R. Zini, S. Salati, E. Bianchi, C. Gemelli, M. Montanari, T. Vignudelli, T. Zanolco-Marani, S. Parenti, P. Paolucci, G. Martinelli, P. P. Piccaluga, M. Baccarani, G. Specchia, U. Torelli, and S. Ferrari. 2006. Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. *Leukemia* 20:1751-1758.
7. Nygren, M. K., G. Dosen, M. E. Hystad, H. Stubberud, S. Funderud, and E. Rian. 2007. Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. *Br J Haematol* 136:400-413.
8. Sjoblom, T., S. Jones, L. D. Wood, D. W. Parsons, J. Lin, T. D. Barber, D. Mandelker, R. J. Leary, J. Ptak, N. Silliman, S. Szabo, P. Buckhaults, C. Farrell, P. Meeh, S. D. Markowitz, J. Willis, D. Dawson, J. K. Willson, A. F. Gazdar, J. Hartigan, L. Wu, C. Liu, G. Parmigiani, B. H. Park, K. E. Bachman, N. Papadopoulos, B. Vogelstein, K. W. Kinzler, and V. E. Velculescu. 2006. The consensus coding sequences of human breast and colorectal cancers. *Science* 314:268-274.
9. Wang, Y., B. A. Schulte, A. C. LaRue, M. Ogawa, and D. Zhou. 2006. Total body irradiation selectively induces murine hematopoietic stem cell senescence. *Blood* 107:358-366.
10. Tothova, Z., R. Kollipara, B. J. Huntly, B. H. Lee, D. H. Castrillon, D. E. Cullen, E. P. McDowell, S. Lazo-Kallanian, I. R. Williams, C. Sears, S. A. Armstrong, E. Passegue, R. A. DePinho, and D. G. Gilliland. 2007. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell* 128:325-339.
11. Ito, K., A. Hirao, F. Arai, S. Matsuoka, K. Takubo, I. Hamaguchi, K. Nomiyama, K. Hosokawa, K. Sakurada, N. Nakagata, Y. Ikeda, T. W. Mak, and T. Suda. 2004. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. *Nature* 431:997-1002.
12. Liu, J., L. Cao, J. Chen, S. Song, I. H. Lee, C. Quijano, H. Liu, K. Keyvanfar, H. Chen, L. Y. Cao, B. H. Ahn, N. G. Kumar, Rovira, II, X. L. Xu, M. van Lohuizen, N. Motoyama, C. X. Deng, and T. Finkel. 2009. Bmi1 regulates mitochondrial function and the DNA damage response pathway. *Nature* 459:387-392.

13. Lazarowski, E. R., D. A. Shea, R. C. Boucher, and T. K. Harden. 2003. Release of cellular UDP-glucose as a potential extracellular signaling molecule. *Mol Pharmacol* 63:1190-1197.
14. Kollet, O., A. Dar, S. Shivtiel, A. Kalinkovich, K. Lapid, Y. Sztainberg, M. Tesio, R. M. Samstein, P. Goichberg, A. Spiegel, A. Elson, and T. Lapidot. 2006. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. *Nat Med* 12:657-664.

Appendices

N/A